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Amyloid-PET predicts inhibition of de novo plaque formation
upon chronic γ-secretase modulator treatment
M Brendel1,10, A Jaworska2,3,10, J Herms2,4,10, J Trambauer5,10, C Rötzer1, F-J Gildehaus1, J Carlsen1, P Cumming6, J Bylund7, T Luebbers8,
P Bartenstein1,4, H Steiner2,5,10, C Haass2,4,5,10, K Baumann9,10 and A Rominger1,4,10
In a positron-emission tomography (PET) study with the β-amyloid (Aβ) tracer [18F]-ﬂorbetaben, we previously showed that Aβ
deposition in transgenic mice expressing Swedish mutant APP (APP-Swe) mice can be tracked in vivo. γ-Secretase modulators
(GSMs) are promising therapeutic agents by reducing generation of the aggregation prone Aβ42 species without blocking general
γ-secretase activity. We now aimed to investigate the effects of a novel GSM [8-(4-Fluoro-phenyl)-[1,2,4]triazolo[1,5–a]pyridin-2-yl]-
[1-(3-methyl-[1,2,4]thiadiazol-5-yl)-piperidin-4-yl]-amine (RO5506284) displaying high potency in vitro and in vivo on amyloid plaque
burden and used longitudinal Aβ-microPET to trace individual animals. Female transgenic (TG) APP-Swe mice aged 12 months (m)
were assigned to vehicle (TG-VEH, n= 12) and treatment groups (TG-GSM, n= 12), which received daily RO5506284 (30 mg kg− 1)
treatment for 6 months. A total of 131 Aβ-PET recordings were acquired at baseline (12 months), follow-up 1 (16 months) and
follow-up 2 (18 months, termination scan), whereupon histological and biochemical analyses of Aβ were performed. We analyzed
the PET data as VOI-based cortical standard-uptake-value ratios (SUVR), using cerebellum as reference region. Individual plaque
load assessed by PET remained nearly constant in the TG-GSM group during 6 months of RO5506284 treatment, whereas it
increased progressively in the TG-VEH group. Baseline SUVR in TG-GSM mice correlated with Δ%-SUVR, indicating individual
response prediction. Insoluble Aβ42 was reduced by 56% in the TG-GSM versus the TG-VEH group relative to the individual baseline
plaque load estimates. Furthermore, plaque size histograms showed differing distribution between groups of TG mice, with fewer
small plaques in TG-GSM animals. Taken together, in the ﬁrst Aβ-PET study monitoring prolonged treatment with a potent GSM in
an AD mouse model, we found clear attenuation of de novo amyloidogenesis. Moreover, longitudinal PET allows non-invasive
assessment of individual plaque-load kinetics, thereby accommodating inter-animal variations.
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INTRODUCTION
With its exponentially increasing incidence as a function of age,
Alzheimer’s disease (AD) has become the most common form of
dementia, and is imposing a signiﬁcant burden on health care
systems of societies with aging populations.1 Neuroﬁbrillary
tangles and amyloid plaques are the histologically characterizing
hallmarks of AD.2 The principal component of amyloid plaques,
the β-amyloid (Aβ) peptide, is a heterogeneous cleavage product
of the Aβ precursor protein (APP) generated by β- and γ-secretase.
Of the several Aβ variants the Aβ42 species is widely believed to be
a key factor of the disease.3 Current therapeutic options for AD
include acetylcholinesterase inhibitors4 and NMDA receptor
antagonists,5 both of which provide some transient amelioration
of cognitive symptoms, but without any disease-modifying
effects.6,7 Consequently, there is an urgent need for disease-
modifying treatments such as those targeting amyloidosis.
γ-Secretase inhibitors (GSIs) suppress intestinal cell differentiation
and also lymphopoiesis, owing to inhibition of Notch signaling8
and a large phase III clinical trial was terminated owing to severe
side effects.9 However, γ-secretase inhibition may still be a hopeful
approach,10 although pharmaceutical companies may stay away
from such efforts. First generation unselective GSIs affect dendritic
spine plasticity,11 which may explain reports of cognitive
deterioration in AD patients with long-term GSI treatment.9,12
Interestingly, however, Notch-sparing GSIs do not seem to affect
spines.13 In contrast to GSIs, γ-secretase modulators (GSMs) shift
Aβ production from the more toxic Aβ42 to shorter forms, which
are less apt to form amyloid aggregates. This favorable modulation of
γ-secretase is obtained without affecting signaling cleavages of
Notch or other critical substrates.14–16 In recent years highly
potent GSMs have been developed, which target γ-secretase in
the N-terminal fragment of its catalytic subunit presenilin.17–20
Owing to their proﬁle of modulating rather than inhibiting γ-
secretase cleavage, GSMs hold great potential as therapeutics with
improved safety, reducing the underlying disease pathology
which might ultimately alter the course of the disease.
Recent testing of several GSMs in transgenic mice showed
reduced plaque area fraction in cortex and hippocampus, as well
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as lower plaque density during chronic treatment.21–23 A number
of chronic GSM treatment studies in Tg2576 mice revealed a dose-
dependent reduction of brain Aβ42 levels,
21,22,24,25 whereas Rogers
et al.24,25 also observed a signiﬁcant decrease of total Aβ levels.
As shown in previous studies, small animal positron-emission
tomography (PET) is a suitable non-invasive tool for monitoring
the amyloid plaque load of transgenic mice in vivo,26–28 yielding
excellent correlations with histological or biochemical assess-
ments. As these transgenic models entail a large inter-animal
heterogeneity with regard to extent of the pathology,29 conducting
longitudinal PET studies in individual animals is highly desirable.27
In accordance with animal protection regulations such studies may
also help to reduce the number of animals required.
Given this background, we aimed to monitor the progression of
amyloidosis in vivo in APP-Swe mice treated for 6 months with the
novel GSM [8-(4-Fluoro-phenyl)-[1,2,4]triazolo[1,5–a]pyridin-2-yl]-
[1-(3-methyl-[1,2,4]thiadiazol-5-yl)-piperidin-4-yl]-amine
(RO5506284) by means of small animal amyloid PET with [18F]-
ﬂorbetaben followed by ex vivo multimodal histological and
biochemical assessment. We found that the GSM treatment
effectively lowered de novo amyloidogenesis over time and that
longitudinal amyloid-PET monitoring effectively copes with the
known inter-animal variability making it superior to classical end
point analyses.
MATERIALS AND METHODS
Synthesis of RO5506284
RO5506284 (Figure 1a) was prepared as described in the patent
literature.30
GSM potency and selectivity
In vitro drug potency determination was performed in H4 and N2A cells
overexpressing APP containing the Swedish mutation (K670N, M671L).
Dose-response curves to determine IC50 values for Aβ modulation by
RO5506284 were generated as outlined previously31 with the following
modiﬁcation: Quantiﬁcation of human or mouse Aβ42 levels in cell culture
supernatant were performed using AlphaLISA kit (PerkinElmer, Waltham,
MA, USA) according to the manufacturer's instructions. The cellular Notch
reporter assay used a stably transfected HEK293 cell line expressing
human Notch1 and a luciferase reporter32 (further details are listed in
Supplementary Information).
Animals
All experiments were performed in compliance with the Swiss federal
regulations (acute treatment arm) and National Guidelines for Animal
Protection, Germany, (chronic treatment arm) with approval of the local
animal care committee of the Government of Oberbayern (Regierung
Oberbayern), and overseen by a veterinarian. Transgenic APP-Swe mice
overexpress human APP with the Swedish mutation driven by the mouse
Thy1.2 promoter33 (further details are listed in Supplementary Informa-
tion). Age-matched C57Bl/6 mice served as controls.
Acute treatments and dose ﬁnding
For acute in vivo treatment of APP-Swe mice, the compound was
administered once per os (gavage) at different doses from 3–100mg kg− 1
and different time points from 2–24 h. Vehicle for the acute treatment was
5% ethanol (VWR Prolabo, Darmstadt, Germany), and 10% solutol (BASF
Chemtrade GmbH, Burgbernheim, Germany) dissolved in sterile water
(Baxter, Compton, UK). For chronic treatment, animals were administered a
daily dose of 30mg kg− 1 per os (gavage) over a period of 6 months.
Vehicle for chronic treatment was 0.9% (w/v) NaCl in 0.3% (v/v) Tween-80
microsuspended in sterile water, thus avoiding potential effects of long-
term ethanol administration. Mice were killed by cervical dislocation at the
indicated time after a single oral administration of drug or vehicle. Brains
were collected, frozen on dry ice and stored at − 80 °C until analysis of
soluble cerebral Aβ. For the determination of soluble Aβ levels, a pre-
viously described procedure was used34 (details are listed in Supplemen-
tary Information). Correlation of in vivo with in vitro potency was estimated
using pharmacokinetic (PK) and pharmacodynamics (PD) analysis, plasma
protein binding determination and P-glycoprotein assessment (details are
listed in Supplementary Information).
Chronic treatment arm
Groups of 24 female APP-Swe transgenic (TG) and C57Bl/6 wild-type (WT)
mice were randomized to either treatment (TG-GSM; WT-GSM) or vehicle
(TG-VEH; WT-VEH) groups at the age of 12 months (Figure 2a), based on
assumptions for a type I error α=0.05, a power of 0.8 and a drop-out rate
of 15% during follow-up. At 12 months, a baseline [18F]-ﬂorbetaben-PET
scan (Aβ-PET) was performed, followed by initiation of daily oral
RO5506284 treatment or vehicle, for a period of 6 months. Follow-up
Aβ-PET-scans were acquired at 16 and 18 months of age, the termination
of the study. Mice were killed after completion of the ﬁnal Aβ-PET-scan,
and brains were histologically and biochemically analyzed. Table 1
provides a detailed overview on study groups and analyses performed.
GSM plasma level assessment
Described in Supplementary Information.
Aβ extraction from brain and quantiﬁcation
Upon completion of the ﬁnal Aβ-PET recording, mice were killed while
deeply anesthetized. The brains were removed and bisected. Hemispheres
intended for biochemical analysis were directly frozen by immersion in
liquid nitrogen. The soluble Aβ pool was extracted as described above and
in Supplementary Information. For detailed description on extracting the
insoluble Aβ pool and determination of Aβ species see Supplementary
Information.
Aβ-PET
Aβ-PET image acquisition, reconstruction and analysis followed a
standardized protocol, as previously published27 and is described in more
detail in the Supplementary Information. Corresponding SUVRCTX/CBL
values were calculated for all groups at each Aβ-PET-scan and individual
longitudinal changes were calculated between baseline and follow-ups at
16 and 18 months of age (Δ%-SUVRCTX/CBL).
Histochemical analyses
Fibrillary Aβ plaques were stained with the ﬂuorescent dye methoxy-X04
(0.01mgml− 1 in phosphate-buffered saline at pH 7.4 for 15min).35 Further
details are described in Supplementary Information. Plaque load was
calculated as the summed area of all plaques relative to the frontal cortex
area. Plaque density was calculated as the number of plaques relative to
frontal cortex area.27 These analyses were performed by an operator blind
to the Aβ-PET results.
Statistics
Group comparisons of VOI-based Aβ-PET results were performed with
multivariate analysis of variance using IBM SPSS Statistics (Version 22.0,
Chicago, IL, USA). Histology and biochemistry data were compared
between treated and untreated transgenic mice by multivariate analysis
of covariance using Aβ-PET baseline estimates as a covariate. For
correlation analyses, Pearson coefﬁcients of correlation (r) were calculated.
Plaque size distributions were compared with a χ2 test followed by the
Kolmogorov–Smirnov test with Prism V5.04 software (GraphPad Software,
San Diego, CA, USA). A Shapiro–Wilk test was performed to verify normal
distribution of sample values. A threshold of Po0.05 was considered to be
signiﬁcant for rejection of the null hypothesis.
RESULTS
RO5506284 is a potent GSM
We ﬁrst characterized the properties of RO5506284 (Figure 1a), a
potent GSM, which selectively lowers Aβ42 and Aβ40 whereas
increasing the Aβ38 concentrations. This proﬁle is typical for many
GSMs of this compound class, which is characterized by a bridged-
aromatic scaffold.17,22,31,36 The IC50 for inhibition of Aβ42 produc-
tion in human H4 neuroglioma cells and mouse N2A cells both
overexpressing human APP-Swe were 25.7 nM (±7.0 s.e.m., n= 4)
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and 13 nM (±3.1 s.e.m., n= 2), respectively. No inhibition of Notch
processing was observed up to concentrations of 4 μM (n= 4;
Figure 1b).
Acute in vivo effects and dose ﬁnding
In acute in vivo treatment studies, RO5506284 showed a dose-
dependent decrease of brain Aβ42 production in young APP-Swe
mice after a single oral dose. Aβ42 levels were signiﬁcantly
reduced by 40, 48 and 73% at 4 h after treatment with single
doses of 10, 30 and 100mg kg− 1 per os (Po0.001, tested by one-
way analysis of variance, Dunnett's multiple comparisons test),
respectively. Corresponding increases of brain Aβ38 levels were
observed, whereas no major change of total brain Aβ levels were
observed (Figure 1c).
The in vivo total plasma IC50 was estimated to be 1340 ngml
− 1
and the free plasma IC50 was calculated to be 15 nM which is in
good correlation of in vitro potency of 13 nM. On the basis of the
PK/PD analysis, a single dose of 30 mg kg− 1 was anticipated to
produce a maximal Aβ42 reduction of ~ 60% at 3 h post dose, a
reduction of 50% at 4 h and a return to baseline after 24 h.
Chronic GSM treatment effects
The study plan of the chronic treatment arm is outlined in
Figure 2a. Details of animal drop outs are provided in Supple-
mentary Information. PK/PD analysis based on RO5506284
exposure in APP-Swe mice after the last day of dosing (similar
PK in WT was observed) and generated acute brain Aβ42 effect
data suggested an average reduction of brain Aβ42 levels over the
treatment period in the range of 20–25% (Figure 2b). Upon daily
chronic treatment with 30mg kg− 1 RO5506284 for 6 months, the
concentration of insoluble Aβ42 was 40% lower in the TG-GSM vs
the TG-VEH group (Po0.05; Figure 2c), whereas amounts of
the other Aβ species did not differ signiﬁcantly (Table 1). Our
randomization of TG mice resulted in allocation of three animals
to the TG-GSM group with elevated Aβ-PET (42 s.d.) at the start of
treatment (labeled with arrows in Figure 2c). This required scaling
of results to the individual baseline amyloid level determined by
PET (see below) using multivariate analysis of covariance, thereby
accounting for much of the inter-animal variability. Upon making
this adjustment, Aβ42 was considerably lower in TG-GSM than in
TG-VEH (−56%; Po0.001; Figure 2d), whereas amounts of the
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Figure 1. (a) Chemical structure of RO5506284 ([8-(4-Fluoro-phenyl)-[1,2,4]triazolo[1,5–a]pyridin-2-yl]-[1-(3-methyl-[1,2,4]thiadiazol-5-yl)-
piperidin-4-yl]-amine). (b) In vitro potency of RO5506284 in human H4 and mouse N2A cells overexpressing Swedish mutant APP on Aβ42
secretion; and effect on Notch processing in the HEK293 cell reporter assay. (c) Reduction of brain Aβ42 was determined in an acute study
where the animals were killed 4 h post-treatment. Each bar represents the mean of n= 5 (n= 4 at 100mg kg− 1) animals. Young 3-month old,
pre-amyloid Tg mice were used for this study to determine the changes of soluble brain Aβ following acute γ-secretase modulation with
RO5506284. A dose-dependent decrease of brain Aβ42 (upper panel) and a corresponding increase of Aβ38 (mid panel) can be observed,
without major effect in total Aβ levels (lower panel). *indicates statistically signiﬁcant at Po0.05; ***indicates statistically signiﬁcant at
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other Aβ species again did not differ signiﬁcantly. Overall, chronic
RO5506284 treatment caused a robust reduction of brain Aβ
deposition, with greatest inﬂuence on the Aβ42 fraction.
Aβ-PET allows monitoring GSM efﬁcacy in vivo
Besides demonstrating that RO5506284 is a potent GSM, substan-
tially lowering brain Aβ42 levels in vivo upon single or prolonged
treatment, monitoring with non-invasive Aβ-PET imaging was
performed (see Figure 2a), acquiring a total of 131 microPET
recordings. This molecular imaging technique was applied with
the intention to accommodate the large inter-individual differ-
ences in initial plaque load and kinetics, thus affording sensitive
detection of individual treatment effects on amyloid plaque
burden.
Baseline results showed a trend towards elevated SUVRCTX/CBL
(+4.2%; P= 0.11) in the TG-GSM group compared with TG-VEH,
mainly driven by the three individual animals mentioned above
(labeled with arrows in Figure 3a). The rather high inter-animal
variation of the amyloid plaque burden further supports the need
of non-invasive techniques, which allows determining longitudin-
ally the amyloid plaque load and kinetics in individual animals
during a therapeutic study. Thus, as exempliﬁed in Figure 3b:
Animal #05 is one individual with high baseline amyloid level,
which turned out to be less effectively treated, whereas animal
#06 had low baseline Aβ, which did not accumulate further during
follow-up, consistent with a good response to RO5506284 treatment.
Animal #21 is a representative untreated individual, in which serial
PET revealed a steady increase from a low baseline amyloid level.
At study termination, mean SUVRCTX/CBL was 9.1% lower (Po0.05)
in the TG-GSM mice than in the TG-VEH group (Figure 3c). When
considering the individual plaque load kinetics, Δ%-SUVRCTX/CBL,
remained nearly constant in the TG-GSM group during 6 months
of RO5506284 treatment (+2.6 ± 6.1%), whereas Δ%-SUVRCTX/CBL in
the TG-VEH group increased by +17 ± 7% (Po0.001; Figure 3d).
Neither group of WT mice showed any signiﬁcant longitudinal
changes in SUVRCTX/CBL (Table 1). Baseline SUVRCTX/CBL in the
TG-GSM group correlated with Δ%-SUVRCTX/CBL (r= 0.67, Po0.05),
whereas Δ%-SUVRCTX/CBL results in the TG-VEH group showed no
correlation with baseline SUVRCTX/CBL (r=−0.03, P=non signiﬁcant;
Figure 3e). Therefore Aβ-PET allowed the prediction of individual
treatment success upon chronic GSM administration.
Post mortem histochemical analyses conﬁrm the Aβ-PET data
To conﬁrm and extend the in vivo results, methoxy-X04 staining of
ﬁbrillar Aβ was performed after the ﬁnal Aβ-PET scan to investi-
gate whether chronic RO5506284 treatment has an impact on
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plaque load, density or size. Plaque load in the TG-GSM mice was
reduced by 42% relative to the TG-VEH group (Po0.05; Figure 4a),
whereas plaque density was 48% lower in the TG-GSM group
compared with TG-VEH mice (Po0.05; Figure 4b). Furthermore,
histogram plotting of plaque size revealed differing distributions
between groups of TG mice, showing fewer (Po0.001) small
plaques (sizeo800 μm2) in TG-GSM animals (Figure 4c). Reduced
numbers of small plaques in TG-GSM animals is consistent with a
primary effect of RO5506284 on de novo amyloidogenesis, as
exempliﬁed in mouse #5 and #6 with only few but rather large
plaques, whereas the TG-VEH animal #21 had a considerable
number of small plaques (Figure 4d).
Terminal measurements correlate highly across modalities
There was a high correlation between ﬁnal Aβ-PET ﬁndings and
plaque density (r= 0.84; Po0.001; Figure 4e), plaque load (r= 0.79;
Po0.001; Supplementary Information), and insoluble Aβ42 levels
(r= 0.83; Po0.001; Figure 4f) as assessed in the corresponding
hemisphere. Likewise, insoluble Aβ42 levels highly correlated with
plaque density (r= 0.81; Po0.001; Figure 4g) and plaque load
(r= 0.77; Po0.001; Supplementary Information) as assessed in the
contralateral hemisphere.
DISCUSSION
This is the ﬁrst large-scale longitudinal Aβ-PET study of cerebral
amyloidosis in a transgenic AD mouse model treated with a
chronic disease-modifying therapy. The study also entails corro-
borative histopathological, as well as biochemical analyses, thus
encompassing three different readout modalities for monitoring
amyloidogenesis. We found that daily oral GSM treatment
commencing at 12 months attenuated the subsequent rate of
de novo amyloidogenesis, which supports current thinking that
early initiation of intervention should be most beneﬁcial.
Aβ-PET improves detection of GSM effects by accounting for inter-
animal variability and predicts outcome
We elected to start GSM treatment at the age of 12 months in
consideration that discernible plaque formation is just barely
evident in APP-Swe animals at the age of 9 months.33 In general,
individual plaque loads are quite heterogeneous in AD mouse
models, most notably at an early age.27,37 Starting treatment at
12 months, in order to accommodate the considerable variability
of individual plaque loads, enabled us to predict response rates as
a function of baseline plaque load with Aβ-PET. In the present
APP-Swe mouse study, Aβ42 levels, density of ﬁbillar Aβ plaques
and Aβ-PET signal at 18 months, all correlated well, and displayed
comparable treatment effects in the contrast between TG-GSM
and TG-VEH groups (Figure 4e–g). However, detection of the real
longitudinal effect of GSM treatment was hampered by the
slightly higher amyloidosis in the TG-GSM group at therapy
initiation. We attribute this to chance, such that (after randomiza-
tion) 3 of 12 mice of the TG-GSM cohort had an Aβ-PET signal at
study baseline exceeding that in the saline-treated control group
(42 s.d.), indicating presence of established brain amyloidosis at
only 12 months of age (Figure 3c). Despite RO5506284 treatment,
the total Aβ levels at study termination were 430% higher in
these three mice compared with any other TG mouse, indicating
not only early onset, but also enhanced progression in these
animals. High variability of the transgene expression is well known
in this strain, and, indeed, among many transgenic AD mouse
models.33,37 This phenomenon indicates that larger group
numbers may be necessary in order to obtain better group
randomization; alternately, results of baseline Aβ-PET-scans could
be used to allocate individuals to comparable groups prior to
initiation of interventions. However, the present Aβ-PET design
partially accommodates the imperfect randomization byT
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accounting for elevated baseline Aβ levels in three individuals
through calculation of Δ%-SUVRCTX/CBL, and by affording the
possibility to adjust for the Aβ-PET baseline covariate in other
histological and biochemical readouts. The longitudinal Aβ-PET
approach sensitively detected the GSM treatment effects in the
group as a whole, thus avoiding false–positive or false-negative
results owing to the imperfect group randomization.
Our study revealed that high amyloid SUVRCTX/CBL at baseline
Aβ-PET recordings correlated positively with further increases in
Aβ-PET signal despite treatment. Those animals with a relatively
low cortical Aβ-PET signal at treatment start still had relatively low
plaque burden at study termination. These preclinical ﬁndings
that pre-existing amyloidosis is a poor precondition for therapy
response are consistent with failed treatment trials of sympto-
matic AD patients, in whom amyloidosis may already have run its
course, or otherwise produced irreversible damage.38–42
Reduced Aβ42 levels in RO5506284 treated APP-Swe mice
primarily lead to inhibition of de novo amyloidogenesis
It is well known that of the various APP processing products Aβ42
has a particularly high amyloidogenic potential and is responsible
for the initiation of plaque formation.43 Although our PK/PD
analysis based on acute effect data suggested only 20–25%
reduction of brain Aβ42, over the treatment period we observed a
signiﬁcant effect on the amyloid pathology in the Tg2576 mouse
model. Indeed, we found pronounced reductions (−56%;
Po0.005) of ﬁbrillar Aβ plaques stained with methoxy-X04 in
the TG-GSM group compared with TG-VEH at study termination.
Signiﬁcantly fewer small-sized plaques were seen in the TG-GSM
animals, leading us to conclude that primarily de novo amyloido-
genesis is sensitive to GSM treatment (Figure 4c). This positive
result seems in line with a previous GSM treatment study in
Tg2576 mice, which suggested that the modulator used in this
study was likewise effective in inhibiting initiation of new Aβ
plaques, but less effective in inhibiting the growth of pre-existing
ones.21 Our present ﬁndings of effects on amyloid protein levels
are also consistent with other reports on preclinical GSM
interventions. Thus, Rogers et al.24 found a dose-dependent
reduction of Aβ42 and a decrease of total Aβ in Tg2576 mice
treated with EVP-0015962 for 50 weeks. Imbimbo et al.21 detected
a reduction of Aβ42 and a decrease of Aβ40 in Tg2576 mice treated
with CHF5074 for 17 weeks, whereas Kounnas et al.22 found
reduced Aβ42, Aβ40 and Aβ38 in Tg2576 mice treated with a
bridged-aromatic scaffold GSM for 7 months. Van Broeck et al.25
administered antibodies against soluble and deposited Aβ, which
APP-Swe Vehicle
APP-Swe RO5506284 (30mg/kg/d)
treatment time (months)treatment time (months)
*
***
PET: SUVRCTX/CBL BL
APP-Swe Vehicle
APP-Swe RO5506284 (30mg/kg/d)
APP-Swe Vehicle
APP-Swe RO5506284 (30mg/kg/d)
Vehicle
RO5506284
R = -0.03
Figure 3. (a) Individual Aβ-PET estimates from baseline (12 months) to termination (18 months). Longitudinal courses of SUVRCTX/CBL for each
mouse are depicted by individual lines. Symbols and lines for representative mice #5 and #6 (TG-GSM, red), as well as mouse #21 (TG-VEH,
green) are accentuated. (b) Axial slices of Aβ-PET images from mice #5, #6 and #21 at each study point superimposed on an MRI atlas. (c)
Absolute SUVRCTX/CBL values for each of the three PET scanning times are shown for TG-GSM (red) and TG-VEH (green) mice. The thick line
marks the mean value, whereas the ﬁlled area indicates the s.d. for all mice. *indicates statistically signiﬁcant at Po0.05. (d) Percentage
increase of follow-up and termination SUVRCTX/CBL relative to individual baseline values for TG-GSM (red) and TG-VEH (green) mice. The thick
line marks the mean value, whereas the ﬁlled area indicates the s.d. of all mice. ***indicates statistically signiﬁcant at Po0.001. (e) Response
prediction by means of Aβ-PET. The percentage increase from baseline to termination SUVRCTX/CBL is depicted as a function of the individual
baseline value. For the TG-GSM, a low baseline value predicted a lesser increase in amyloidosis during treatment, whereas mice with a high
baseline value had a high increase despite treatment. For the TG-VEH, there was a remarkable increase in SUVRCTX/CBL, which was not a
function of the individual baseline value. The correlations (r) between the percentage increase and the baseline value are indicated.
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Figure 4. (a) Plaque load (%) in both TG groups assessed by methoxy-X04 staining. Each dot represents the histochemically determined
plaque load, using Aβ-PET baseline estimate as covariate. Red indicates TG-GSM animals and green shows TG-VEH animals. (b) Plaque density
using Aβ-PET baseline estimate as covariate for one hemisphere of each TG mouse. Red indicates TG-GSM animals and green shows TG-VEH
animals. The horizontal line in the middle represents the mean value. *indicates statistically signiﬁcant at Po0.05. (c) Histogram plotting of
plaque size revealed a differing distribution between groups of TG mice, with signiﬁcantly fewer small plaques in the TG-GSM animals (red).
(d) Methoxy-X04 staining of representative sagittal slices in the three above mentioned animals, the right panel zooms into the areas with the
largest clusters of amyloid plaques in frontal parts of cerebral cortex. (e) Correlation of ﬁnal Aβ-PET estimates and plaque density shows
excellent agreement. Corresponding hemispheres were used from TG-GSM (red squares) and TG-VEH (green circles) animals for this
comparison. (f) Correlation of ﬁnal Aβ-PET estimates and insoluble Aβ42 levels shows excellent agreement. Corresponding hemispheres were
used from TG-GSM (red squares) and TG-VEH (green circles) animals for this comparison. (g) Correlation of Aβ42 levels and plaque density
shows excellent agreement. Contralateral hemispheres were used from TG-GSM (red squares) and TG-VEH (green circles) animals for this
comparison.
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evoked at 7 months, a dose-dependent decrease of Aβ42,
decreased Aβ40 and a reduction of Aβ38 in Tg2576 mice.
Recommendation for upcoming treatment trials targeting Aβ-
pathology
Because a suitable antibody clears the existing Aβ deposits,
whereas a GSM could also prevent de novo amyloidogenesis, we
suppose that a combination treatment might prove even more
efﬁcacious than single treatment paradigms in reducing amyloi-
dosis. Another important outcome of our study is that the serial
assessment with Aβ-PET throughout the course of a long-term
treatment study, in conjunction with histopathological and
biochemical end point analyses, appears to be superior to simpler
experimental paradigms, in which only the end point readouts are
obtained. Given the well known inter-animal variability observed
in this study, parallel Aβ-PET monitoring during the course of
treatment, as well as normalization of results to baseline Aβ-PET
makes the ﬁndings obtained at study end more robust and
meaningful. We propose that application of serial Aβ-PET during
treatment studies will allow for faster translation of disease-
modifying approaches from the preclinical stage to the clinic.
Limitations
As we tested only a single dose up to 30mg kg− 1 of the GSM
RO5506284, we cannot be certain that the maximum possible
effect with minimum side effects was obtained. However, present
results will provide the basis for designing a suitably powered
dose-response study.
In addition, our design was not informative about protection
against cognitive changes or impaired brain energy metabolism,
as documented in a study by Martin-Moreno et al.44 However, this
does not detract for our major objective, which was to obtain
serial Aβ-PET and terminal biochemical measurements of histolo-
gical plaque load and Aβ levels in all animals.
CONCLUSION
This is the ﬁrst large-scale serial Aβ-PET study during prolonged
GSM treatment in a transgenic AD model. Multimodal data
included biochemical and histopathological ﬁndings, in addition
to the serial, non-invasive Aβ-PET investigations, which accom-
modated the large inter-individual differences in initial plaque
load and kinetics, thus affording sensitive detection of treatment
effects. Prediction of treatment response was facilitated by
individual Aβ-PET measurements of baseline amyloid level. GSM
treatment with RO5506284 attenuated de novo amyloidogenesis
compared with vehicle, in line with the notion that early treatment
initiation is most likely to be beneﬁcial. The modalities applied
should not be considered in competition but rather are comple-
mentary and add further value to any single modality alone.
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